Sun Borui, Zhang Chun, Lin Ting, Liu Sinan, Wang Zheng, Zhang Jingyao, Liu Chang
Department of Anesthesiology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Jun;31(6):714-718. doi: 10.3760/cma.j.issn.2095-4352.2019.06.011.
To evaluate the clinical efficacy and safety of continuous renal replacement therapy (CRRT) in patients with severe acute pancreatitis (SAP) receiving percutaneous drainage (PCD).
Clinical data of SAP patients receiving PCD admitted to department of hepatobiliary surgery of the First Affiliated Hospital of Xi'an Jiaotong University from November 11th 2015 to May 13th 2018 were retrospectively analyzed. The patients were divided into CRRT group and control group according to whether or not receiving CRRT. Demographic data, relevant variables before and after PCD, complication and outcome were all compared.
A total of 75 patients were included in the study, 30 were treated with application of CRRT and 45 without CRRT. (1) There was no significant difference in gender, age, body mass index (BMI), medical history (smoking, drinking), complications (cardiovascular disease, chronic lung disease, diabetes, chronic renal insufficiency), etiology (gallstone, alcohol abuse, hyperlipidemia and others), or white blood cell count (WBC), C-reactive protein (CRP), serum procalcitonin (PCT), fluid resuscitation, mechanical ventilation, vasoactive agent or intra-abdominal pressure within 48 hours after admission between the two groups. However, acute physiology and chronic health evaluation II (APACHE II) score within 48 hours after admission of CRRT group was significantly higher than that of control group (18.3±4.5 vs. 12.8±6.2, P < 0.05). (2) There was no significant difference in WBC, PCT, APACHE II score or computed tomography severity index (CTSI) before PCD between the two groups. There was no significant difference in the position or times of PCD procedure between the two groups, but the time interval of PCD in the CRRT group was significantly longer than that in the control group (days: 19.4±5.4 vs. 12.8±2.2, P < 0.05). Meanwhile, there was no significant difference in drainage of fluid properties, incidence of abdominal bleeding, infection, gastrointestinal fistula, endoscopic removal of necrotic tissue, laparotomy for removal of necrotic tissue or the time from PCD to endoscopy or laparotomy between two groups. However, the length of intensive care unit (ICU) stay and the length of hospital stay in the CRRT group were significantly longer than those in the control group (days: 23.2±8.5 vs. 15.3±12.1, 51.2±21.2 vs. 31.2±14.0, both P < 0.01). (3) Kaplan-Meier survival analysis showed that there was no significant differences in 1-year or 3-year cumulative survival rates between the two groups (χ = 0.097, P = 0.755; χ = 0.013, P = 0.908).
CRRT is safe and feasible in the treatment of SAP patients receiving PCD procedure. It does not increase the risk of bleeding and may delay the time interval of PCD intervention. However, it may prolong the length of ICU stay and the length of hospital stay. It should be worthy of much attention for clinicians.
评估连续性肾脏替代疗法(CRRT)在接受经皮引流(PCD)的重症急性胰腺炎(SAP)患者中的临床疗效及安全性。
回顾性分析2015年11月11日至2018年5月13日西安交通大学第一附属医院肝胆外科收治的接受PCD的SAP患者的临床资料。根据是否接受CRRT将患者分为CRRT组和对照组。比较两组的人口统计学数据、PCD前后的相关变量、并发症及结局。
本研究共纳入75例患者,30例接受CRRT治疗,45例未接受CRRT治疗。(1)两组在性别、年龄、体重指数(BMI)、病史(吸烟、饮酒)、并发症(心血管疾病、慢性肺病、糖尿病、慢性肾功能不全)、病因(胆结石、酒精滥用、高脂血症等)或入院后48小时内的白细胞计数(WBC)、C反应蛋白(CRP)、血清降钙素原(PCT)、液体复苏、机械通气、血管活性药物或腹内压方面无显著差异。然而,CRRT组入院后48小时内的急性生理与慢性健康状况评分II(APACHE II)显著高于对照组(18.3±4.5对12.8±6.2,P<0.05)。(2)两组PCD前的WBC、PCT、APACHE II评分或计算机断层扫描严重程度指数(CTSI)无显著差异。两组PCD操作的部位或次数无显著差异,但CRRT组PCD的时间间隔显著长于对照组(天数:19.4±5.4对12.8±2.2,P<0.05)。同时,两组在引流液性质、腹腔出血、感染、胃肠瘘、内镜下坏死组织清除、剖腹手术清除坏死组织或从PCD到内镜或剖腹手术的时间方面无显著差异。然而,CRRT组的重症监护病房(ICU)住院时间和住院时间显著长于对照组(天数:23.2±8.5对15.3±12.1,51.2±21.2对31.2±14.0,均P<0.01)。()3 Kaplan-Meier生存分析显示,两组1年或3年累积生存率无显著差异(χ=0.097,P=0.755;χ=0.013,P=0.908)。
CRRT治疗接受PCD的SAP患者安全可行。它不会增加出血风险,可能会延迟PCD干预的时间间隔。然而,它可能会延长ICU住院时间和住院时间。临床医生应予以高度关注。